24 September, 2026 | Thursday
BioPharma Boardroom
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...

May 05, 2023 | Friday | News
Sapience Therapeutics Awarded $2M Grant to Evaluate Therapeutic Potential of ST316, a First-in-Class Antagonist.

The proposed non-clinical studies will investigate pharmacodynamic biomarkers for ST316, a first-in-class β-catenin antagonist, and evaluate the impac...

May 05, 2023 | Friday | News

Partner Content

BioPharma BreakThrough's

Editor Picks

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
  View poll results   More polls
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
BioPharma Boardroom

About Us Media Pack Contact Us Privacy Policy

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close